Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate
Metrics: PDF 1504 views | HTML 2769 views | ?
Jessica L. Rausch1, Sergei Boichuk1,4, Areej A. Ali1, Sneha S. Patil,1 Lijun Liu1, Donna M. Lee1, Matthew F. Brown1, Kathleen R. Makielski1, Ying Liu1, Takahiro Taguchi2, Shih-Fan Kuan3, Anette Duensing1,3
1Cancer Therapeutics Program, University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA, USA
2Department of Anatomy, Kochi Medical School, Nankoku Kochi, Japan
3Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
4Current address: Department of Pathology, Kazan State Medical University, Kazan, Russia
Anette Duensing, email: email@example.com
Keywords: gastrointestinal stromal tumor (GIST), imatinib mesylate, KIT, ABL1
Received: June 30, 2016 Accepted: December 05, 2016 Published: December 10, 2016
Most gastrointestinal stromal tumors (GISTs) are caused by activating mutations of the KIT receptor tyrosine kinase. The small molecule inhibitor imatinib mesylate was initially developed to target the ABL1 kinase, which is constitutively activated through chromosomal translocation in BCR-ABL1-positive chronic myeloid leukemia. Because of cross-reactivity of imatinib against the KIT kinase, the drug is also successfully used for the treatment of GIST. Although inhibition of KIT clearly has a major role in the therapeutic response of GIST to imatinib, the contribution of concomitant inhibition of ABL in this context has never been explored. We show here that ABL1 is expressed in the majority of GISTs, including human GIST cell lines. Using siRNA-mediated knockdown, we demonstrate that depletion of KIT in conjunction with ABL1 – hence mimicking imatinib treatment – leads to reduced apoptosis induction and attenuated inhibition of cellular proliferation when compared to depletion of KIT alone. These results are explained by an increased activity of the AKT survival kinase, which is mediated by the cyclin-dependent kinase CDK2, likely through direct phosphorylation. Our results highlight that distinct inhibitory properties of targeted agents can impede antitumor effects and hence provide insights for rational drug development. Novel KIT-targeted agents to treat GIST should therefore comprise an increased specificity for KIT while at the same time displaying a reduced ability to inhibit ABL1.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.